JPWO2022158528A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2022158528A5
JPWO2022158528A5 JP2022576742A JP2022576742A JPWO2022158528A5 JP WO2022158528 A5 JPWO2022158528 A5 JP WO2022158528A5 JP 2022576742 A JP2022576742 A JP 2022576742A JP 2022576742 A JP2022576742 A JP 2022576742A JP WO2022158528 A5 JPWO2022158528 A5 JP WO2022158528A5
Authority
JP
Japan
Prior art keywords
group
pharmaceutical composition
carbon atoms
composition according
hydrogen atom
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022576742A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2022158528A1 (https=
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/JP2022/001997 external-priority patent/WO2022158528A1/ja
Publication of JPWO2022158528A1 publication Critical patent/JPWO2022158528A1/ja
Publication of JPWO2022158528A5 publication Critical patent/JPWO2022158528A5/ja
Pending legal-status Critical Current

Links

JP2022576742A 2021-01-20 2022-01-20 Pending JPWO2022158528A1 (https=)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2021007531 2021-01-20
PCT/JP2022/001997 WO2022158528A1 (ja) 2021-01-20 2022-01-20 抗ウイルス剤

Publications (2)

Publication Number Publication Date
JPWO2022158528A1 JPWO2022158528A1 (https=) 2022-07-28
JPWO2022158528A5 true JPWO2022158528A5 (https=) 2025-01-28

Family

ID=82549509

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022576742A Pending JPWO2022158528A1 (https=) 2021-01-20 2022-01-20

Country Status (8)

Country Link
US (1) US20240131046A1 (https=)
EP (1) EP4282420A4 (https=)
JP (1) JPWO2022158528A1 (https=)
KR (1) KR20230137361A (https=)
CN (1) CN116761615A (https=)
AU (1) AU2022210132A1 (https=)
CA (1) CA3206486A1 (https=)
WO (1) WO2022158528A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT4122926T (lt) * 2021-04-14 2025-07-25 Shionogi & Co., Ltd. Triazino dariniai, turintys virusų replikaciją slopinantį poveikį, ir juos apimanti farmacinė kompozicija
CN116782904A (zh) * 2021-09-28 2023-09-19 盐野义制药株式会社 含有三嗪衍生物的医药组合物
AU2022353486A1 (en) * 2021-09-28 2024-05-02 National University Corporation Hokkaido University Pharmaceutical composition containing triazine derivative
WO2023054292A1 (ja) * 2021-09-28 2023-04-06 塩野義製薬株式会社 トリアジン誘導体を含有する医薬組成物
EP4289432A4 (en) * 2021-11-24 2025-01-15 Shionogi & Co., Ltd PREPARATION FOR ORAL ADMINISTRATION CONTAINING TRIAZINE DERIVATIVES
WO2023054732A2 (ja) * 2022-01-19 2023-04-06 塩野義製薬株式会社 新型コロナウイルス感染症治療用医薬
EP4603099A1 (en) * 2022-10-04 2025-08-20 Manabu Igarashi Anti-influenza virus composition, medicine, food, beverage, supplement, agricultural chemical, feed and cosmetic
WO2024076951A2 (en) * 2022-10-04 2024-04-11 The Scripps Research Institute Antiviral prodrugs and formulations thereof
CN117357531A (zh) * 2023-09-08 2024-01-09 湖北九康通生物医药有限公司 一种药物组合物、其制备方法和其应用
CN117417387A (zh) * 2023-09-13 2024-01-19 苏州翔实医药发展有限公司 一种核苷类似物的合成方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005020885A2 (en) * 2003-05-21 2005-03-10 Isis Pharmaceuticals, Inc. Compositions and methods for the treatment of severe acute respiratory syndrome (sars)
US11738025B2 (en) * 2020-02-04 2023-08-29 Oyagen, Inc. Method for treating coronavirus infections
KR20230020952A (ko) * 2020-04-01 2023-02-13 유니온 테라퓨틱스 에이/에스 치료
PH12021552872A1 (en) * 2020-04-05 2022-03-21 Pfizer Compounds and methods for the treatment of covid-19
WO2021209993A1 (en) * 2020-04-13 2021-10-21 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Use of metabolic regulators for the treatment of covid-19
GB2599799B (en) * 2020-04-15 2023-04-05 Starpharma Pty Ltd Macromolecule for prophylaxis of Coronavirus
EP3912628A1 (en) * 2020-05-20 2021-11-24 Institut de Recherche en Semiochimie et Ethologie Appliquée Nucleoside analogues to inhibit the main protease of a coronavirus
MX2023006518A (es) * 2020-12-03 2023-06-23 Regeneron Pharma Metodos de identificacion de sujetos que tienen un mayor riesgo de desarrollar una infeccion por coronavirus y su tratamiento.

Similar Documents

Publication Publication Date Title
JPWO2022158528A5 (https=)
JP2010539241A5 (https=)
US9676808B2 (en) 2′,4′-substituted nucleosides as antiviral agents
JP2011521903A5 (https=)
JP2011518835A5 (https=)
RU2403258C2 (ru) Тиазолилдигидроиндазолы
RU2405774C2 (ru) Гетероциклические ингибиторы аспартилпротеазы
EP1321463B1 (en) Thiazole derivatives and their use for the treatment or prevention of Flavivirus infections
JP2014514308A5 (https=)
ME01294B (me) Nova jedinjenja i kompozicije i metode upotrebe
JP5837936B2 (ja) アルキルスルフィニル置換チアゾリド化合物
JP2012517444A5 (https=)
RU2010112408A (ru) Фосфадиазиновые ингибиторы iv полимеразы hcv
CA2653034A1 (en) Macrocyclic oximyl hepatitis c protease inhibitors
JP2024001048A5 (https=)
CA2490200A1 (en) 2' and 3'-nucleoside prodrugs for treating flaviviridae infections
AR036672A1 (es) Derivados de pirrolidinona
JP2006515858A5 (https=)
RU2008119842A (ru) Производные триазола в качестве ингибиторов 11-бета-гидроксистероиддегидрогеназы-1
KR950700265A (ko) 고지혈증 치료에 유용한 벤조티아제핀 화합물(hypolipidaemic ben zothiazepine compounds)
JP2016505551A5 (https=)
JPWO2023106310A5 (https=)
JP2021529159A5 (https=)
JPWO2023095860A5 (https=)
JP2023549494A5 (https=)